2,5293,1128,6774,347 Net proceeds from secondary public offering
--149,661-Net cash (used in)/generated from financing activities(74,337)3,520(33,528)4,755Net (decrease)/increase in cash and cash equivalents(48,176)(19,856)2,626(39,296)Cash and cash equivalents at beginning of period
255,084118,746204,228137,502Effect of exchange rate changes on cash
4,3677244,4211,408Cash and cash equivalents at end of period211,27599,614211,27599,614Exhibit 4 MINDRAY MEDICAL INTERNATIONAL LIMITEDRECONCILIATIONS OF NON-GAAP RESULTS OF OPERATIONS MEASURES TO THE NEAREST COMPARABLE GAAP MEASURES(Dollars in thousands, except for share and per share data)Three months ended June 30,Six months ended June 30, 2010 2011 2010 2011 (unaudited)(unaudited)(unaudited)(unaudited) US$ US$ US$ US$ Non-GAAP net income45,88749,84086,03292,062Non-GAAP net margin25.6%22.9%26.5%23.1%Amortization of acquired intangible assets(1,868)(1,783)(4,000)(3,550)Deferred tax impact related to acquired intangible assets513414168Share-based compensation(1,788)(3,282)(3,694)(6,061)GAAP net income 42,28244,80978,47982,519GAAP net margin23.6%20.6%24.1%20.7%Non-GAAP basic earnings per share0.400.430.760.80Non-GAAP diluted earnings per share0.390.420.740.78GAAP basic earnings per share0.370.380.700.72GAAP diluted earnings per share0.360.370.670.70 Shares used in computation of: Basic earnings per share 114,299,570116,504,103112,779,472115,026,629 Diluted earnings per share 118,139,
|SOURCE Mindray Medical International Limited|
Copyright©2010 PR Newswire.
All rights reserved